Bruns Ingmar

Bruns Ingmar is listed in filings as Chief Medical Officer at Zentalis Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through Feb 10, 2026, including sale activity and purchase activity. Recent filings connect the profile to Zentalis Pharmaceuticals, Inc. (ZNTL). The current snapshot covers public activity from Dec 3, 2024 to Feb 10, 2026. Reported amounts are shown as $802 to $1.0M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.